Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

EANS-News: Intercell completed the acquisition of Cytos' antibody technology platform

Vienna (Austria), June 8, 2010 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Strategic management decisions
Intercell AG (VSE:
ICLL) today announced the closing of the acquisition of Cytos' 
platform technology for monoclonal antibody discovery. On May 6, 2010
Intercell had announced the intent to acquire that technology, which 
is based on expression cloning of monoclonal antibodies from human 
B-cells, for EUR 15m.
The antibody technology complements Intercell's technology platforms 
and opens novel medically and commercially relevant applications for 
Intercell's Antigen Identification Program (AIP®).
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG
  • 04.06.2010 – 17:31

    EANS-News: Announcement regarding the upcoming Annual Shareholders´ Meeting

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Annual & Special Corporate Meetings Vienna (Austria), June 4, 2010 (euro adhoc) - - I. The ordinary shareholders´ meeting of Intercell AG for the business year 2010 will take place on Friday, June 25, 2010, at 2.00 p.m. at the ...

  • 11.05.2010 – 07:39

    EANS-Adhoc: Intercell AG announces Q1 2010 results and updates on R&D progress

    ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report 11.05.2010 Good progress in vaccine development programs - Strong R&D spending in late-stage programs lead to EUR 14.7 m loss in the first quarter Vienna (Austria), May 11, 2010 - ...